Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 13, 2000

Primary Completion Date

January 23, 2003

Study Completion Date

July 20, 2006

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

temozolomide

DRUG

thalidomide

Trial Locations (11)

10021

Memorial Sloan-Kettering Cancer Center, New York

15213

University of Pittsburgh Cancer Institute, Pittsburgh

20892

Neuro-Oncology Branch, Bethesda

53792

University of Wisconsin Comprehensive Cancer Center, Madison

77030

University of Texas - MD Anderson Cancer Center, Houston

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

02115

Dana-Farber Cancer Institute, Boston

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

75235-9154

Simmons Cancer Center - Dallas, Dallas

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00006358 - Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor | Biotech Hunter | Biotech Hunter